NEW YORK – Researchers at the Dana-Farber Cancer Institute, Harvard Medical School, and elsewhere have discovered a peripheral immune signature that is associated with responsiveness to anti-PD-1 therapy in Hodgkin lymphoma patients.
NEW YORK – Researchers at the Dana-Farber Cancer Institute, Harvard Medical School, and elsewhere have discovered a peripheral immune signature that is associated with responsiveness to anti-PD-1 therapy in Hodgkin lymphoma patients.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.